Board Meeting10 Aug 2026, 03:26 pm
Windlas Biotech Approves Unaudited Q1 FY27 Financial Results
AI Summary
Windlas Biotech Ltd announced that its Board of Directors, in a meeting held on August 10, 2026, approved the Unaudited Standalone Financial Results for the quarter ended June 30, 2026. The company also submitted the Limited Review Report from its auditors. The board meeting commenced at 2:30 PM and concluded at 3:15 PM. The company noted that it is no longer required to prepare consolidated financial statements as its non-operating US subsidiary has been dissolved.
Key Highlights
- Board approved unaudited standalone financial results for Q1 FY27.
- Results pertain to the quarter ended June 30, 2026.
- Limited Review Report from auditors was submitted.
- Consolidated financial statements are no longer required.
- Subsidiary dissolution effective March 31, 2026.
Price Impact
More from WINDLAS*